Anxiety disorders are widespread and increasing. During the pandemic, 41.7% of U.S. adults reported anxiety symptoms. Despite this prevalence, only 38.2% of U.S. adults with an anxiety disorder received mental health services in a recent year.
Key Takeaways
- In the U.S., anxiety disorder prevalence increases with age up to young adulthood and then declines (2019): 31.1% age 18–29
- Globally, the number of people with anxiety disorders increased from 1990 to 2019 by 14.0% (age-standardized rates roughly stable; estimated prevalence increase)
- In the U.S., the prevalence of anxiety disorder among adults peaked at 2018 values after rising during 2010–2018 (NHIS trend)
- 18.0% of U.S. adults had posttraumatic stress disorder (PTSD) in their lifetime (2019) — categorized under trauma- and stressor-related disorders but commonly assessed alongside anxiety disorders in population surveys
- Only 38.2% of adults with anxiety disorders in the U.S. received any mental health service (2019)
- 31.9% of adults in the U.S. who needed mental health treatment reported they did not receive it (2022)
- In the UK, 47.6% of referrals for IAPT were treated within 18 weeks in 2022/23; the remainder were outside target
- In the U.S., anxiety disorders contribute to 32.3 million missed workdays annually (2018)
- $1.14 trillion annual economic cost of anxiety disorders globally (2016 estimates)
- $4.2 billion annual U.S. cost attributable to anxiety disorders related to healthcare utilization (2015)
- About 60% of patients receiving CBT for anxiety show reliable improvement (meta-analysis estimate)
- In a large meta-analysis, CBT for anxiety disorders had a pooled effect size of g≈0.9 versus control (2014)
- For panic disorder, combined CBT plus pharmacotherapy improves panic symptoms with about 1.2× greater reduction than either alone (systematic review estimate)
- 10.3% of adults in England had probable anxiety (HSE 2022)
- 32% of adults with anxiety disorders reported that their condition interfered with work or school
Only about 38% of Americans with anxiety disorders receive mental health services, driving major personal and economic costs.
Related reading
01 · Category
Epidemiology Trends8 stats
01
In the U.S., anxiety disorder prevalence increases with age up to young adulthood and then declines (2019): 31.1% age 18–29
02
Globally, the number of people with anxiety disorders increased from 1990 to 2019 by 14.0% (age-standardized rates roughly stable; estimated prevalence increase)
03
In the U.S., the prevalence of anxiety disorder among adults peaked at 2018 values after rising during 2010–2018 (NHIS trend)
04
During COVID-19, 41.7% of U.S. adults reported symptoms of anxiety at some level (2020)
05
In 2021, 31.0% of college students in the U.S. reported moderate to severe anxiety symptoms (systematic survey data)
06
In the U.S., anxiety symptoms among adolescents increased from 25.7% in 2019 to 34.3% in 2021 (Youth Risk Behavior Survey)
07
In England, 2023/24 IAPT service data show year-on-year increases in referrals for anxiety (quarterly trend)
08
In Australia, anxiety disorders were among the top three mental disorders by prevalence in 2022 (AIHW estimates)
Interpretation
Epidemiology Trends Interpretation
Across epidemiology trends, anxiety burden is rising in key recent periods with U.S. adult and youth symptom rates climbing from 25.7% in 2019 to 34.3% in 2021 among adolescents and 31.1% prevalence among adults aged 18 to 29 in 2019, while globally the number of people with anxiety disorders increased by 14.0% from 1990 to 2019.
02 · Category
Prevalence1 stats
01
18.0% of U.S. adults had posttraumatic stress disorder (PTSD) in their lifetime (2019) — categorized under trauma- and stressor-related disorders but commonly assessed alongside anxiety disorders in population surveys
Interpretation
Prevalence Interpretation
In terms of prevalence, about 18.0% of U.S. adults reported having PTSD at some point in their lifetime in 2019, highlighting that this condition is relatively common among the population.
03 · Category
Treatment Gap5 stats
01
Only 38.2% of adults with anxiety disorders in the U.S. received any mental health service (2019)
02
31.9% of adults in the U.S. who needed mental health treatment reported they did not receive it (2022)
03
In the UK, 47.6% of referrals for IAPT were treated within 18 weeks in 2022/23; the remainder were outside target
04
In the U.S., 61.8% of adults with major depressive episode (MDE) or anxiety disorders did not receive treatment (2019)
05
In Australia, 14.4% of people with anxiety disorders did not receive any treatment in the previous 12 months (2023)
Interpretation
Treatment Gap Interpretation
The treatment gap for anxiety is substantial, with only 38.2% of U.S. adults receiving any mental health service in 2019 and 61.8% of adults with major depressive episode or anxiety disorders not getting treatment, showing that most people who could benefit are still left outside care.
04 · Category
Economic Impact5 stats
01
In the U.S., anxiety disorders contribute to 32.3 million missed workdays annually (2018)
02
$1.14 trillion annual economic cost of anxiety disorders globally (2016 estimates)
03
$4.2 billion annual U.S. cost attributable to anxiety disorders related to healthcare utilization (2015)
04
In a U.S. claims database study, anxiety disorders were associated with 1.6× higher total healthcare costs than matched controls (2019)
05
In the U.S., anxiety disorders contribute to about 12.1% of all disability days in working-age adults (2016)
Interpretation
Economic Impact Interpretation
Anxiety disorders impose a substantial economic burden in the category of economic impact, with 32.3 million missed workdays in the U.S. each year and global costs reaching $1.14 trillion annually, while U.S. healthcare-related expenses alone total $4.2 billion per year and account for about 12.1% of all disability days in working-age adults.
05 · Category
Treatment Outcomes10 stats
01
About 60% of patients receiving CBT for anxiety show reliable improvement (meta-analysis estimate)
02
In a large meta-analysis, CBT for anxiety disorders had a pooled effect size of g≈0.9 versus control (2014)
03
For panic disorder, combined CBT plus pharmacotherapy improves panic symptoms with about 1.2× greater reduction than either alone (systematic review estimate)
04
SSRIs and SNRIs are first-line for many anxiety disorders; response rates are commonly ~40%–60% in clinical trials (systematic review range)
05
Exposure-based CBT is associated with symptom reductions in social anxiety disorder; pooled odds ratio for response ~2.4 (systematic review)
06
A randomized trial found internet-based CBT reduced anxiety symptoms by a standardized mean difference of −0.64 vs control at post-treatment (2013)
07
Digital CBT (iCBT) for anxiety disorders showed symptom improvement with standardized mean difference of about −0.5 in meta-analyses (2019)
08
In a meta-analysis, mindfulness-based interventions reduced anxiety symptoms with pooled effect size d≈0.63 (2014)
09
For generalized anxiety disorder, pharmacotherapy (e.g., SSRIs) achieves response rates around 45%–55% in trials (review estimate)
10
In the STAR*D study, about 33% of patients achieved remission at some point during treatment for anxiety comorbidities (subset analysis)
Interpretation
Treatment Outcomes Interpretation
Overall, treatment outcomes for anxiety look consistently favorable, with around 60% of patients showing reliable improvement on CBT and meta-analytic effects near g≈0.9, while for more targeted approaches like exposure-based CBT and combined CBT plus pharmacotherapy benefits are even stronger.
More related reading
06 · Category
Prevalence & Demographics2 stats
01
10.3% of adults in England had probable anxiety (HSE 2022)
02
32% of adults with anxiety disorders reported that their condition interfered with work or school
Interpretation
Prevalence & Demographics Interpretation
In England, 10.3% of adults have probable anxiety, and among those with anxiety disorders 32% say it affects their work or school, showing that this prevalence is tied to meaningful real world impact within the Prevalence and Demographics category.
07 · Category
Healthcare Access3 stats
01
41.7% of U.S. adults reported symptoms of anxiety at some level during COVID-19 (2020)
02
27% of U.S. adults with mental health needs reported delaying care because of cost in 2023
03
37% of U.S. adults with a mental health condition reported a mental health-related unmet need for care (2022)
Interpretation
Healthcare Access Interpretation
Even before and during the pandemic, about 41.7% of U.S. adults reported anxiety symptoms, and later data show that cost and unmet needs still limit care access with 27% delaying mental health services due to cost in 2023 and 37% reporting an unmet need for mental health-related care in 2022.
08 · Category
Cost & Workforce Impact5 stats
01
$15.6 billion in annual U.S. employer health spending is attributed to anxiety and depression (2021)
02
$1.2 billion annual U.S. spending on anxiety-related outpatient mental health visits (2018)
03
12% of U.S. workers reported anxiety affected their productivity in the last month (2022)
04
33% of global total DALYs for mental disorders are attributable to anxiety disorders (2019)
05
8.2% of global health spending is directed toward mental health, and anxiety disorders are a major component of that burden (2019)
Interpretation
Cost & Workforce Impact Interpretation
With anxiety driving $15.6 billion in annual U.S. employer health spending and 12% of U.S. workers reporting productivity impacts, it is clear that anxiety disorders are a major cost and workforce burden rather than only a personal health issue.
09 · Category
Clinical Effectiveness6 stats
01
In a network meta-analysis, cognitive behavioral therapy (CBT) had one of the highest probabilities of being among the most effective treatments for anxiety disorders (2018)
02
Exposure-based interventions for anxiety disorders produced a pooled effect corresponding to an absolute improvement of about 0.33 SD over control in trials (2016)
03
76% of participants receiving CBT for anxiety in a pragmatic real-world study achieved clinically meaningful improvement at 3 months (2021)
04
Serotonin-norepinephrine reuptake inhibitors (SNRIs) improved generalized anxiety disorder symptoms with standardized mean differences around −0.35 versus placebo in a meta-analysis (2019)
05
Mindfulness-based cognitive therapy showed symptom reductions for anxiety in randomized trials with a standardized effect around −0.40 at post-treatment (2019)
06
Relapse prevention after CBT for anxiety reduced relapse risk by 40% over follow-up compared with minimal intervention (2016 meta-analysis)
Interpretation
Clinical Effectiveness Interpretation
For Clinical Effectiveness, the evidence suggests that anxiety treatments are often meaningfully effective in practice, with CBT showing a 76% 3 month clinically meaningful improvement in real world care and exposure based approaches delivering about a 0.33 SD absolute improvement while CBT also lowers relapse risk by 40% versus minimal intervention.
10 · Category
Market & Technology4 stats
01
11% annual CAGR projected for the digital mental health market for anxiety-focused solutions through 2030 (2024 vendor forecast)
02
8.9% of U.S. adults reported using at least one mental health app in the past year (2022)
03
Telehealth accounted for 32% of mental health visits in the U.S. during 2020 (Medicaid and commercial claims analysis)
04
Remote monitoring adoption for anxiety-related programs reached 14% of behavioral health organizations in the U.S. in 2023 (survey)
Interpretation
Market & Technology Interpretation
From 2024 to 2030, the digital mental health market for anxiety-focused solutions is projected to grow at an 11% annual CAGR, while U.S. adoption signals are already strong with 8.9% of adults using mental health apps, 32% of visits shifting to telehealth in 2020, and remote monitoring reaching 14% of behavioral health organizations in 2023.
report visual · Projection
Anxiety symptoms surged during COVID-19
A large share of U.S. adults reported anxiety symptoms during the COVID-19 period, with subsequent surveys capturing continued elevated levels.
25.7 Percent
Start
+9.83%
CAGR · 2y
31 Percent
Projected
20202022
source-verifiedjamanetwork.com · cdc.gov · nacada.ksu.edu · medrxiv.org2021
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Priya Chandrasekaran. (2026, February 13). Anxiety Disorder Statistics. Gitnux. https://gitnux.org/anxiety-disorder-statistics
MLA
Priya Chandrasekaran. "Anxiety Disorder Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/anxiety-disorder-statistics.
Chicago
Priya Chandrasekaran. 2026. "Anxiety Disorder Statistics." Gitnux. https://gitnux.org/anxiety-disorder-statistics.
Sources & references
49 datasets cited across this report · attribution is report-level
+21 additional datasets cited (not shown individually)